Pharmaceutical & Biotechnology Report Available Now
Pharmaceutical & Biotechnology Sector Report
In our newly published report on the Pharmaceutical & Biotechnology Sector, we look at the Key Findings, performances and trends in the sector, takeaways on Risks & Opportunities, and more. V.E’s Pharmaceuticals and Biotechnology sector is composed of 188 companies. These companies are engaged in the research, development, manufacturing, and distribution of drugs for human or veterinary use. The medicines produced are aimed to cure or manage diseases, or to prevent from infection.
The industry’s value chain starts with the manufacturing of medicines that involves research and development in addition to regulatory approval. The second phase includes the distribution and the handling of medicines from the manufacturer to the end user (through retail, pharmacy, hospital, or dispensing doctors). The final step in the value chain is the commercialisation and the provision of the right medicine dosage, form, and advice to the right patient.
The Pharmaceuticals & Biotechnology sector is composed of two broad sub-sectors: biotechnology companies and traditional pharmaceuticals and the primary difference between the two is the method by which the drugs are produced:
Pharmaceutical companies manufacture drugs through a series of chemical synthesis. Based on their size and strategy, pharmaceutical companies may conduct extensive in-house research or seek to license drugs from other pharmaceutical or biotechnology companies. Some pharmaceutical companies are considered as specialty pharma since they focus only on specific activities such as R&D only or marketing and sales only. Pharmaceutical companies generally hold the exclusive rights to manufacture and distribute their drugs for five years.
Biotechnology companies produce drugs with a biological basis that are manufactured in living organisms such as bacteria or enzymes. These companies are working to duplicate or change the function of a living cell and could use genetics research to develop products for human diseases and conditions. Biotechnology companies hold their patents for 12 years.
Vigeo Eiris (V.E) was acquired by Moody’s Corporation in 2019 and officially became a part of Moody’s ESG Solutions Group in 2020. The V.E brand name is now being retired and replaced with Moody’s ESG Solutions. Existing customers: please note that your access to our platforms and data services will continue without interruption. From December 1st 2021, the content pages on the V.E website will no longer be updated. However, content on this website will remain active for archive purposes only. Please visit www.moodys.com/esg-solutions to find our latest product information on ESG data and assessments, Second Party Opinions, Sustainability Ratings, as well as ESG research and insights. Moody’s ESG Solutions is committed to producing superior ESG insights that empower organizations to better understand ESG performance and make better decisions. Please contact us at MESG@moodys.com if you would like to know more.